Bio-Rad introduces Unity Next Peer QC
Oct. 14, 2022—Bio-Rad Laboratories has launched Unity Next Peer QC, a quality control peer comparison software that provides instant access to peer reporting and comprehensive quality control data.
Webinars and Sponsored Roundtables — Register Now
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
ZeptoMetrix releases flu, RSV, SARS-CoV-2 external run control
Oct. 13, 2022—ZeptoMetrix has released its NATtrol external run control for flu A and B, RSV B, and SARS-CoV-2, for research use only.
mTuitive, Gestalt partner to enhance pathology reporting
Oct. 11, 2022—mTuitive and Gestalt Diagnostics announced a partnership to enhance reporting for pathology laboratories.
FDA clears NanoZoomer S360MD slide scanner system
Oct. 10, 2022—Hamamatsu Photonics announced that the FDA granted 510(k) clearance to market the NanoZoomer S360MD high-throughput, automated slide scanner system for primary diagnostic use.
Randox releases MRSA/MSSA PCR test on Vivalytic system
Oct. 7, 2022—Randox Laboratories has added its MRSA/SA test to the Vivalytic system.
FDA clears Boston Cell Standards IHC controls for HER2, ER, PR
Oct. 6, 2022—Boston Cell Standards today announced it received 510(k) clearance from the FDA for its IHControls breast cancer panel, positive controls to monitor the performance of the immunohistochemical staining process for HER2, ER, and PR IHC assays.
Roche CDx approved to ID patients eligible for Enhertu
Oct. 5, 2022—Roche announced that the FDA has approved the Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with HER2-low metastatic breast cancer for whom Enhertu (fam-trastuzumab deruxtecan-nxki) may be considered as a targeted treatment. Enhertu is a specifically engineered HER2-directed antibody drug conjugate developed and commercialized by AstraZeneca and Daiichi Sankyo.
NovoPath adds capabilities to NovoPath 360
Oct. 3, 2022—NovoPath today announced the release of enhanced integrated workflows to its software-as-a-service–based LIS platform, NovoPath 360.
Illumina unveils NovaSeq X series
Sept. 29, 2022—Illumina today announced the launch of the NovaSeq X series—NovaSeq X and NovaSeq X Plus—production-scale sequencers, which aim to enable faster, more powerful, and more sustainable sequencing.
Oncomine Dx Target test approved to ID patients for Retevmo
Sept. 28, 2022—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic to aid in selecting patients with RET-fusion positive locally advanced or metastatic non-small cell lung cancer, RET-fusion positive advanced or metastatic thyroid cancer, and RET-mutation positive advanced or metastatic medullary thyroid cancer who may be eligible for treatment with Lilly’s Retevmo (selpercatinib).